How stroma cells trigger tumour angiogenesis

Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.  

Read more

Jennewein Biotechnologie expands into Chinese market

Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.

Read more

Medicxi put €40m into two Sosei spin off companies

Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.

Read more

Hitachi expands European reach in cell and gene therapy

Hitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.

Read more

Dewpoint Therapeutics kicks off with $60m financing

Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of  devasting diseases.

Read more

IPO: Marinomed sets offer price

Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share. 

Read more

Novozymes partners with Carbios subsidiary Carbiolice

Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.

Read more

Biomarker predicts response to TNF blockers

A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.

Read more

UK launches new payment model for antimicrobials

In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).

Read more